uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma
Show others and affiliations
2013 (English)In: Pediatric Blood & Cancer, ISSN 1545-5009, E-ISSN 1545-5017, Vol. 60, no 8, 1267-1273 p.Article in journal (Refereed) Published
Abstract [en]

Background Recurrences in primary localized alveolar rhabdomyosarcoma (RMA) are common. Post-relapse survival is poor. We evaluated prognostic factors including relapse treatment in patients with recurrent RMA. Methods Relapses occurred in 115/235 patients with nonmetastatic RMA treated in four consecutive CWS-trials after achievement of a complete remission. Sufficient information about post-relapse treatment and outcome could be obtained in 99 patients and was retrospectively analyzed. Results Nine of 99 patients received no salvage therapy and died after a median of 2 months. The remaining 90 patients received multimodal relapse treatment including mandatory chemotherapy. Recurrences were grossly resected in 39 patients; 57 patients received radiation. At a median follow-up from relapse of 8 years, 20 patients were alive and disease-free (5-year post-relapse survival [PROS] 21.3 +/- 8). All surviving patients apart from a single individual had an isolated, circumscribed recurrence. Sixteen of 20 survivors were treated with adequate local relapse therapy (ALRT, i.e., either complete resection or gross resection+radiation). Survival in the subgroup of 27 individuals with circumscribed recurrences and ALRT was significantly better (PROS 53.7 +/- 19) compared with disseminated recurrences and/or tumors treated without ALRT. Absence of primary lymph node involvement, circumscribed relapses, ALRT, and achievement of a second CR were identified as independent favorable risk factors. Conclusion Post-relapse survival for primary localized RMA is generally poor. However, certain patient groups differed significantly in their likelihood of survival and 50% of patients with circumscribed relapses treated with ALRT survived. These findings may form the basis for an evidence-based risk-stratification for recurrent disease including relapse treatment. 

Place, publisher, year, edition, pages
2013. Vol. 60, no 8, 1267-1273 p.
Keyword [en]
alveolar rhabdomyosarcoma, children, recurrence
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-204847DOI: 10.1002/pbc.24488ISI: 000320399800011OAI: oai:DiVA.org:uu-204847DiVA: diva2:640296

On behalf of the Cooperative Weichteilsarkom Studiengruppe (CWS); Presented in part: At the International Society of Paediatric Oncology SIOP XXXX Congress, Berlin, Germany, October 2–6, 2008.

Available from: 2013-08-13 Created: 2013-08-12 Last updated: 2015-03-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ljungman, Gustaf
By organisation
In the same journal
Pediatric Blood & Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 307 hits
ReferencesLink to record
Permanent link

Direct link